글로벌 유전성 혈관부종 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

유전성 혈관 부종 치료 시장 분석

유전성 혈관 부종(HAE) 치료 시장은 인지도 향상과 치료 방식의 상당한 발전으로 인해 상당한 성장이 예상됩니다. 재발성 및 심각한 부종이 특징인 희귀 유전 질환인 HAE는 진단 역량 개선과 환자 기반 증가로 인해 치료적 개입이 증가하고 있습니다. 향상된 유전자 검사 및 바이오마커와 같은 진단 분야의 최근 혁신으로 인해 질환을 더 일찍 정확하게 감지할 수 있게 되어 보다 개인화되고 효과적인 치료가 가능해졌습니다. 고급 C1-에스테라제 억제제, 브라디키닌 B2 수용체 길항제, 칼리크레인 억제제 개발을 포함한 치료 옵션의 기술적 발전으로 치료 효능과 환자 결과가 현저히 개선되었습니다.

유전성 혈관 부종 치료 시장 규모

글로벌 유전성 혈관 부종 치료제 시장 규모는 2023년에 39억 1,000만 달러로 평가되었으며, 2031년까지 76억 3,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 8.72%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

유전성 혈관 부종 치료 시장 동향

“ 개인화된 케어에 대한 더 큰 강조”

개인화된 치료에 대한 더 큰 강조와 치료 선택의 발전은 유전성 혈관 부종(HAE) 치료 시장 성장에 상당히 기여하고 있습니다. 피하 C1-에스테라제 억제제 및 경구 브라디키닌 B2 수용체 길항제와 같은 치료법의 최근 획기적인 발전은 전통적인 정맥 주사 치료보다 더 편리하고 효과적인 환자 중심 솔루션으로의 전환을 보여줍니다. Takeda의 Takhzyro 및 BioCryst의 Orladeyo와 같은 새로운 약물의 승인은 치료 효능과 환자의 삶의 질을 모두 개선하여 맞춤형 접근 방식을 강조하는 이러한 추세를 보여줍니다. 이러한 발전은 특정 환자 요구에 맞게 약물을 개인화하는 더 광범위한 추세를 반영하며, 치료 대안을 더 쉽게 접근하고 사용자 정의할 수 있게 함으로써 상당한 시장 성장을 촉진하고 있습니다.

보고 범위 및 유전성 혈관 부종 치료 시장 세분화

유전성 혈관 부종 치료 시장 정의

Hereditary Angioedema (HAE) Therapeutics refer to the range of medical treatments specifically designed to manage and alleviate the symptoms of Hereditary Angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body. These therapeutics aim to prevent or reduce the frequency and severity of angioedema attacks, addressing the underlying pathophysiology of the condition. Treatments include medications such as C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors, which work to regulate and stabilize the body's inflammatory response. The goal of HAE therapeutics is to improve patient outcomes by minimizing swelling episodes, enhancing quality of life, and offering targeted and effective management options for this chronic condition.

Hereditary Angioedema Therapeutic Market Dynamics

Drivers

• Increasing Awareness Among Healthcare Professionals

Increasing awareness of hereditary angioedema (HAE) among healthcare professionals and patients has significantly improved the early and accurate diagnosis of the condition, driving up the demand for effective therapeutic options. For instance, recent initiatives by organizations such as the hereditary angioedema association (HAEA) have focused on educating both patients and clinicians about the signs and symptoms of HAE, resulting in better identification of the disorder. Consequently, the demand for targeted and innovative therapeutic options, such as c1-esterase inhibitors and bradykinin b2 receptor antagonists, has risen, driving market growth and improving patient outcomes.

• Rising Research and Development (R&D) Investments in Orphan Drug Development

Research and development (R&D) investments in orphan drug development is a pivotal driver of the hereditary angioedema (hae) therapeutic market. Orphan drugs, specifically designed to treat rare diseases such as HAE, benefit from significant financial and regulatory support due to their critical role in addressing unmet medical needs. For instance, the government of Canada announced a total investment of up to $1.5 billion in support of the first-ever national strategy for drugs for rare diseases to help increase access to, and affordability of, promising and effective drugs for rare diseases to improve the health of patients across Canada. Such substantial investment not only accelerates the discovery and commercialization of new treatments but also enhances patient outcomes and drives market expansion by addressing the specific needs of HAE patients.

Opportunities

• Development of Advanced Diagnostic Tools and Biomarkers

The development of advanced diagnostic tools and biomarkers for hereditary angioedema (HAE) is significantly enhancing early and accurate detection, leading to a higher number of diagnosed cases and a subsequent rise in demand for therapeutics. For instance, the introduction of next-generation sequencing (NGS) and genetic testing technologies has allowed for more precise identification of HAE subtypes and genetic mutations associated with the condition, thus facilitating earlier diagnosis. This advancement not only enables personalized treatment plans tailored to the specific genetic profile of patients but also supports more effective management of the disease. Consequently, the increased diagnostic accuracy and early intervention have driven greater demand for targeted therapies and innovative treatments, thus fueling market growth. Enhanced diagnostic capabilities also contribute to better disease monitoring and patient outcomes, further boosting the adoption of advanced therapeutics.

• Advancements in Combination Therapies

Advancements in combination therapies are presenting significant growth opportunities in the hereditary angioedema (HAE) therapeutic market by addressing multiple aspects of disease management simultaneously. Combining different therapeutic agents can provide synergistic effects, enhancing treatment efficacy and patient outcomes. For instance, the combination therapy of biocryst’s orladeyo, an oral kallikrein inhibitor, with takeda's takhzyro, which provides a multi-faceted approach to preventing HAE attacks and managing symptoms. Such integrated strategy not only improves therapeutic outcomes but also broadens the market appeal of combination therapies, as they cater to various patient needs and treatment regimens. As pharmaceutical companies explore and develop these combination therapies, they create new opportunities for market growth and improved patient care.

Restraints/Challenges

• Low Prevalence of the Disease

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, gastrointestinal tract, and airways. Due to its rarity, the prevalence of HAE is relatively low, affecting approximately 1 in 50,000 to 150,000 individuals globally. This limited patient population constrains the overall market size for hae therapeutics, making it a less attractive investment opportunity for pharmaceutical companies. Consequently, pharmaceutical companies may be deterred from investing heavily in research and development for HAE, impacting the availability and variety of treatment options.

• Complexity of Disease Management

Managing hereditary angioedema (HAE) presents a significant market challenge due to the multifaceted approach required for effective disease management. The condition necessitates both acute and prophylactic treatments, involving immediate interventions with intravenous c1-esterase inhibitors or bradykinin b2 receptor antagonists during attacks, and long-term prophylactic therapies such as daily or weekly c1-esterase inhibitors or oral kallikrein inhibitors to reduce attack frequency and severity. This complexity demands personalized treatment plans tailored to individual patient needs, attack frequency, and therapeutic response. The requirement for continuous monitoring and frequent adjustments to treatment regimens adds further difficulty, impacting patient adherence and healthcare provider efficiency. This intricate management landscape poses a challenge for pharmaceutical companies, as developing and delivering effective and adaptable therapies that address the diverse needs of hae patients requires substantial investment and innovation, potentially affecting market growth and accessibility.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hereditary Angioedema Therapeutic Market Scope

The market is segmented on the basis of type, drug class, application, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type I Hereditary Angioedema (HAE)
• Type II Hereditary Angioedema (HAE)
• Type III Hereditary Angioedema (HAE)

 Drug Class

• C-1 Esterase Inhibitors
• Bradykinin B2 Receptor Antagonists
• Kallikrein Inhibitors
• Others

Application

• Prophylaxis
• Treatment

Route of Administration

• Oral
• Injectable

End User

• Home Healthcare
• Hospitals
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Hereditary Angioedema Therapeutic Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, drug class, application, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hereditary angioedema therapeutic market, driven by the continuous launch of innovative products by key pharmaceutical companies. The presence of well-established healthcare infrastructure and increased awareness of rare genetic disorders further supports market growth in the region. Additionally, favorable regulatory frameworks encourage faster approval of new therapies, boosting market expansion.

Asia-Pacific is projected to witness substantial growth in the hereditary angioedema therapeutic market, largely driven by rising patient awareness and improved diagnostic capabilities across the region. Increasing healthcare investments and the expansion of pharmaceutical companies into emerging markets further contribute to the growing availability of advanced treatments. Moreover, government initiatives aimed at enhancing healthcare infrastructure are supporting market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Hereditary Angioedema Therapeutic Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Hereditary Angioedema Therapeutic Market Leaders Operating in the Market Are:

• Takeda Pharmaceutical Company Limited (Japan)
• CSL (Australia)
• BioCryst Pharmaceuticals, Inc. (U.S.)
• Pharming (Netherlands)
• Ionis Pharmaceuticals (U.S.)
• Novartis AG (Switzerland)
• CENTOGENE N.V. (Germany)
• Sanofi (France)
• 칼비스타제약(미국)
• 파이저 주식회사(미국)
• GSK plc. (영국)
• 아스트라제네카(영국)
• 메드트로닉(미국)
• 릴리(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 암젠 주식회사(미국)
• 존슨앤존슨 서비스 주식회사(미국)
• AbbVie Inc.(미국)
• 인사이트(미국)
• Bayer AG(독일)

유전성 혈관 부종 치료 시장의 최신 동향

• 2023년 12월, Ionis Pharmaceuticals는 Otsuka Pharmaceutical과 라이선스 계약을 체결하여 Otsuka에 유럽에서 유전성 혈관 부종(HAE) 치료를 위한 리간드-접합 안티센스 요법인 donidalorsen을 판매할 독점권을 부여했습니다. 이 계약에 따라 Ionis는 요법의 비임상 및 임상 개발을 관리하고 Otsuka는 규제 제출을 처리하고 유럽 전역의 마케팅 노력을 감독합니다.
• 2024년 9월, KalVista Pharmaceuticals, Inc.는 미국 식품의약국(FDA)이 세베트랄스타트에 대한 신약 허가 신청(NDA)을 접수했다고 발표했습니다. 세베트랄스타트는 12세 이상 소아 및 성인 환자의 유전성 혈관 부종(HAE) 발작에 대한 주문형 치료를 위해 설계된 조사용 경구 혈장 칼리크레인 억제제입니다.

SKU-46085